

1 **Title:** Evaluating public and patient involvement in interventional research – a newly
2 developed checklist (EPPIIC) with application to the COB-MS feasibility trial

3 **Authors:**

4 Elise Pyne 1 ,

5 Robert Joyce 2 <https://orcid.org/0000-0001-5572-0804>,

6 Christopher P. Dwyer 3 <https://orcid.org/0000-0001-5935-4338>

7 Sinéad M. Hynes 2* <https://orcid.org/0000-0002-3199-7355>

8

9 1. School of Medicine, College of Medicine, Nursing and Health Sciences, University of
10 Galway, Ireland

11 2. School of Health Sciences, College of Medicine, Nursing and Health Sciences, University
12 of Galway, Ireland

13 3. Senior Researcher, HEA Performance & Dept. of Teacher Education, Technological
14 University of the Shannon, Athlone.

15

16 *Corresponding author

17 E-mail: sinead.hynes@universityofgalway.ie (SMH)

18

19

20

21

22

23 **Abstract**

24 Public and patient involvement (PPI) has been identified as an increasingly desired and,
25 often, required component of trial methodology – leading to higher quality, more accessible
26 and relevant clinical research, alongside increased recruitment, funding success and insight
27 into research impact. However, despite the great variety of frameworks and checklists
28 available for assessing PPI, most are limited with respect to important features (e.g.
29 applicable in specific contexts only, fail to clarify what should be assessed and reported, lack
30 the necessary comprehensiveness or are biased in favour of researcher reporting). Thus, the
31 current research aimed to address such limitations through the development of a new
32 checklist, the EPPIIC, through review, thematic analysis and ‘meta-evaluation’ in
33 conjunction with PPI engagement. A further aim was to pilot the EPPIIC through its
34 application to and reporting on the COB-MS trial, which utilised PPI throughout the
35 research’s life-cycle. Upon completion of the EPPIIC, three thematic ‘sub-scales’ emerged:
36 (1) Policy & Practice, (2) Participatory Culture and (3) Influence & Impact. All findings are
37 presented and discussed in light of theory and research. Notably, findings recommend
38 EPPIIC as a useful means of assessing PPI in future trials.

39

40

41

42

43

44 **Introduction**

45 Public and patient involvement (PPI) is vital for trial methodology, leading to higher quality,
46 more accessible and relevant clinical research (1). It is also rapidly becoming a more-and-
47 more desired – if not required – component of clinical trials (2). Recent approaches to PPI
48 aim to empower and enable such member involvement, allowing for flexible structures and
49 procedures created by both PPI members and researchers. ‘*Nothing about us without us*’ – a
50 message often used by PPI members in context – tells clinical researchers that the raw
51 purpose of their work is to improve the lives of those affected by the topic of their study (3).
52 While researchers may understand the intricate pathology of disease, it is patients who have
53 the unique lived experience of the condition.

54 PPI inclusion further increases recruitment, funding success rates and provides unique
55 insights into the potential impacts of the research (4). For PPI members, involvement can
56 increase skills and boost feelings of self-worth and confidence (5). Notably, *true* PPI extends
57 beyond mere consultation to active partnership throughout the research’s life-cycle – from
58 funding application and protocol development all the way to dissemination and knowledge
59 translation (6). Indeed, through appropriate implementation, PPI members can be the
60 invaluable ‘critical friends’ needed to improve the overall quality of clinical research (7-8).

61 With pressure from funders to embed PPI into clinical research and improved awareness of
62 the benefits of PPI, the rate of PPI in clinical research has rapidly increased (2;9). However,
63 the evidence of PPI impact is less clear, with continued discussion and debate concerning the
64 means of evaluating the use of PPI in clinical trials (10-11). Though there is vast agreement
65 regarding the need to capture the negative and positive aspects of PPI processes (10), there
66 exists a variety of frameworks, surveys and checklists – with diverse perspectives that claim
67 to capture the challenges faced and opportunities created when using PPI in clinical research

68 (12-13). However, the comprehensiveness and focuses of these tools are debatable in light of
69 this diverse pool from which to choose – debate further reinforced by the relative recency of
70 PPI as a phenomenon in clinical trial methodology. Not surprisingly, there also exists a
71 demand for a guideline and/or framework that not only evaluates PPI, but also provides
72 researchers with clarity regarding what *should be* assessed and reported, in context (12).
73 Again, ‘context is key’ and, unfortunately, not all PPI evaluation strategies are contextually
74 appropriate, when such comprehensiveness is desired. Indeed, comparison and appraisal of
75 strategies, assessing impact and ensuring what is claimed has been done, are at the heart of
76 evaluating PPI approaches.

77 None of these extant PPI checklists are without their limitations (13). Most frameworks
78 evaluate from the researcher’s perspective – a strategy that immediately suggests reporting
79 bias. On the other hand, evaluation strategies that do account for PPI members responding are
80 also problematic, with one review finding that only 11.1% of tools had the reading level
81 sufficient for public or lay persons’ understanding (11). Many of these also fail to address the
82 same areas from both perspectives- the PPI member(s) and the researcher(s). Typically PPI
83 members are only questioned on their input rather than the accommodations that have been
84 made for them by the researcher team, whereas researchers have the opportunity to comment
85 on both.

86 Thus, the focus of the current research is to address the limitations of previous evaluation
87 tools through the development of a new checklist, that is generalisable across research
88 typologies within the parameters of clinical interventions through comprehensive description
89 of PPI focuses, though non-specific reporting cues (e.g. with added focus on open-ended
90 reporting). This has been achieved through two overarching aims and through the following
91 objectives:

92 Aim 1: Develop a checklist that can be applied across a variety of research settings:

93 1. To conduct a review of current PPI guidelines and outcome measures.

94 2. To assess the identified outcome measures and collate thematically identified focuses
95 to create an evaluation checklist (or checklists) to appraise the quality of PPI within
96 trials.

97 Aim 2: To pilot this newly developed checklist:

98 3. For application to a trial, Cognitive Occupation-Based programme for people with
99 MS (COB-MS; 14-15; described further in the methods section), to demonstrate its
100 use; and

101 4. To report the COB-MS PPI evaluation.

102

103 **Materials and Methods**

104 To note- the COB-MS PPI member (RJ) was involved throughout the research process
105 described here (and the COB-MS trial) and had a lead role in directing the research.

106 **Aim 1 Methods**

107 **Review of current tools**

108 A literature review of extant PPI checklists was conducted, focusing on the process and
109 outcome assessments of PPI. These checklists were then subjected to content analysis to
110 identify common topics throughout and identify the exact quantitative and qualitative
111 questions and methods to evaluate PPI. This work was completed in consultation with the
112 COB-MS PPI member (RJ). This was carried out with the overall aim of assessing PPI in the
113 COB-MS feasibility trial (14-15). Variations in the style of existing checklists also provided
114 insight in the best way to formulate questions.

115 **Search Strategy**

116 To navigate and formulate the research question, the SPIDER search strategy was used (16;
 117 see Table 1) to ensure the relevant and appropriate frameworks were being evaluated. Other
 118 search methods included a keywords search using PubMed and Google Scholar search
 119 engines. Boolean operators were used to carry out an extensive search of all related research
 120 and documentation (see Table 2).

121 **Table 1 – Identification of research question through SPIDER Search strategy**

S Sample	PI Phenomenon of Interest	D Design	E Evaluation	R Research Type
Various PPI evaluation frameworks used in clinical trials	Efficacy of framework to report PPI	Using PPI Evaluation frameworks and modifying them to fit this trial	Impact of PPI on study recruitment, retention, and overall trial quality	Mixed methods

122

123 **Table 2 - Comprehensive list of keywords used in Boolean operators to identify research**
 124 **concerning PPI evaluation strategies**

Public and Patient Involvement OR PPI OR Patient Engagement OR Patient Participation OR User Involvement	AND	Framework OR checklist OR criteria OR agenda OR Method OR Approach OR Guideline OR model OR Toolkit OR Strategy	AND	Evaluation OR Assessment OR Appraisal
----------------------------------------------------------------------------------------------------------	-----	-----------------------------------------------------------------------------------------------------------------	-----	---------------------------------------

125

126 In addition to the literature review, the Centre of Excellence for Partnership with Patients and
 127 the Public (CEPPP) database was also used to identify relevant checklists for this research.
 128 The CEPPP is an online resource that encompasses a number of evaluation tools, to enable
 129 researchers to assess the quality of PPI in their research. The CEPPP evaluates the included
 130 tools based on usability, comprehensiveness, patient and public perspective and scientific
 131 rigour by applying targeted questions to each framework. From CEPPP’s previous
 132 evaluation, each framework was investigated, with 11 satisfying our inclusion criteria,
 133 included in Table 3 below.

134 **Inclusion / exclusion criteria**

135 The only inclusion criterion for framework evaluation was that the framework must assess
136 PPI in the context of clinical research. Frameworks were excluded if they were not relevant to
137 research or deviated from it -e.g. solely focused on team dynamics and collaboration.

138 **Analysis of Extant Frameworks**

139 After all relevant checklists had been identified, thematic analysis was conducted, to identify,
140 analyse and report themes within the qualitative data. Specifically, data were analysed
141 consistent with Braun and Clarke's (17-18) six-phase analytic process, which highlights three
142 main tasks: familiarisation with data; coding and theme identification; and the reviewing and
143 refining of themes. This method included reading and re-reading of frameworks to a gain
144 familiarity with the materials, prior to identification of components of interesting elements,
145 codes, and approaches. An extensive list was generated and sorted into overarching themes.

146 From this list of themes, a content analysis was completed to formulate the quantitative and
147 qualitative questions required for a comprehensive checklist. Approaches to PPI were divided
148 into formulative and summative questioning, meaning that while some questions related to
149 the process of PPI, others dealt with the final outcomes instead. Developed questions were
150 reviewed to remove any questions that were overlapping, repetitive or were not directly
151 relevant to PPI. Reviewing and refining the checklist items until finalisation and application
152 of the checklist involved the PPI members, research team and an independent researcher who
153 had no involvement with the COB-MS trial under assessment (i.e. to limit potential for bias).

154

155 **Aim 2 Methods**

156 **Applying the newly developed checklist**

157 Following its completion, the checklist was actively applied to evaluate the PPI associated
 158 with the COB-MS trial, ISRCTN11462710, (see 14-15), which utilised PPI throughout the
 159 trial’s life-cycle. Specifically, the trial partnered a PPI member as a contracted researcher
 160 [becoming an *embedded patient researcher* (EPR; 7)], included two PPI members in the Trial
 161 Steering Committee and created an external PPI consultation group.

162

163 **Results**

164 **Aim 1 Results**

165 Through thematic analysis, many overlapping patterns of themes were found. Subthemes
 166 were grouped into their overarching theme to create each of the three main themes. A
 167 summary of the research evidence that led to these subthemes is in the Table 3 below.

168

169 **Table 3 - Summary of themes and subthemes found through a literature review of PPI**
 170 **evaluation tools.**

<u><i>Theme and Subtheme</i></u>	<u><i>Checklists</i></u>
Policy & Practice	
Planned Strategy and Methods	(13; 19- 34),
Resource mobilisation	(13; 19-20; 22-28; 31; 33; 35-37)
Reports of PPI	(13; 19- 24; 26; 28; 31; 33-38)
Recruitment	(32; 35)
Team Engagement	(21-25; 28;31-32)
Adaptability	(13; 19-20; 22; 28; 31; 36-37)
Experience and representation	(13; 22-25; 27; 31; 35)
Management, and Implementation of PPI Recommendations	(13; 19-22; 28; 38)
Communication methods	(23-24; 27; 31-32; 34)
Participatory Culture / Collaboration	
Boosting Awareness	(19-20; 23-24; 28)
Participatory Feedback	(19-20; 22-24; 26; 31; 33-34)
Influencing Outcomes of PPI	(13; 21; 35)

171

172 Three main themes were identified: (1) Policy & Practice, (2) Participatory Culture, and (3)
173 Influence & Impact. *Policy & Practice* focused on the structure and strategy of PPI
174 implementation prior to the research starting, centring on the efficiency and methodological
175 aspects of PPI in research – the justification for which was to assess the preparedness of an
176 organisation to carry out this type of research. This item was included as a measure of
177 meaningful involvement and appropriate consideration of PPI. *Participatory Culture* referred
178 to consideration of factors that could enhance or hinder PPI throughout the project, with
179 focus on the research team’s ability to accommodate PPI and how PPI can be optimally
180 engaged/integrated. Notably, this theme is perhaps the main discussion point for comparing
181 trials that include PPI, focusing on the needs of the PPI members and how to appropriately
182 involve them. Finally, *Influence & Impact* focused largely on outcomes of PPI, ensuring that
183 the experience was beneficial to both researchers and PPI members. It reflects the overall
184 impact of PPI on the research question and exhibits whether the PPI strategies initially
185 proposed were actually implemented. This theme is of particular importance, as it not only
186 reveals the advantage(s) of PPI within the trial being evaluated, but also has the capacity to
187 facilitate recommendations for PPI within future interventions.

188 Following thematic analysis, relevant questions from extant checklists were collated under
189 their relevant themes and subthemes (see Table 3). After filtering initial questions (e.g. by
190 relevance, overlap and repetition) and amending as appropriate, the resulting questions were
191 organised into two separate forms: researcher evaluation and PPI member evaluation. The
192 final questions were generated by reviewing the wording of questions within other checklists
193 and analysing clarity and comprehensiveness. Some of these were used verbatim, while
194 others were adjusted to ensure better understanding of the question. This process was
195 completed in close collaboration with the PPI member (RJ). Such organisation reduces bias
196 and facilitates the ability of independent adjudicators to observe perspectives from distinct

197 sources and compare them. Checklist items were tailored to each audience (e.g. with respect
 198 to ensuring accessible language) but were otherwise commensurate; though the researcher
 199 form includes some additional items (e.g. related to the overall trial budget). Items in the
 200 checklists were presented through means of both ‘box-ticking’ (i.e. both Likert scale and
 201 dichotomous, yes/no responding, as appropriate) and open-ended response. A balanced mix
 202 of formative/summative and qualitative/quantitative inquests were included in both forms.
 203 The finalised checklists, titled “Evaluation of PPI for Interventional research Checklist
 204 (EPPIIC)” can be found in Supporting Information 1 and 2 (S1 and S2 Appendices). A
 205 summary of the steps taken in developing and applying the EPPIIC are in Table 4.

206

207 **Table 4: Summary of steps involved in creation of new EPPIIC.**

	Step	Resources/People involved	Results
1	Compile full list of available checklists	CEPPP Database search (PubMed, Google Scholar)	Total checklists identified (n= 20; 11 CEPP and nine database search)
2	Generate full list of themes	All identified checklists; PPI involvement	Total number of items in the first iteration of the checklist = 34
3	Matching each item with a checklist item	All identified checklists	Checklist items were sorted into each identified theme
4	Grouping subthemes into relevant main themes	PPI involvement; research team discussion	Three overarching themes identified
5	Refining the items	PPI involvement; research team discussion	Decision to separate PPI and researcher evaluation
6	Piloting of the checklist	PPI and research team	Adjustments between PPI member and researcher surveys – e.g. change language, merging of items etc.
7	Finalising the checklist	PPI and research team	Number of items – ensuring equal questions between researcher and PPI member survey with appropriate balance of qualitative and quantitative questioning.
8	Application of the checklist	EPPIIC applied to the COB-MS trial	Results presented below.

208

209 **Aim 2 Results**

210 The EPPIIC (PPI member form) was completed by the trial’s EPR, RJ, while the researcher
211 form was completed by trial PI, SMH. Overall, the checklists identified areas of strengths in
212 terms of PPI inclusion and highlighted areas for future improvement. The results of the
213 application of the checklist are presented under the three themes of the EPPIICs. Direct
214 quotes from the checklists are presented for further context. These results are summarised in
215 Tables 5, 6 and 7, with further description of presented in-text below. Notably, these tables
216 focus on the PPI Member/EPR and researcher perspectives and translates a ‘tick-box’
217 exercise into meaningful results. The checklist asked both cohorts to provide their opinions to
218 statements through a Likert ‘significance’ or ‘agreement’ scale. The box that was chosen by
219 the respondent reflected the strength of their opinion towards the statement provided in each
220 section.

221 **Policy and Practice**

222 In the Policy and Practice section, both checklists reported that the design strategy and reason
223 for PPI was clearly defined prior to the beginning of the trial. Both PPI member and
224 researcher believed the goal of PPI was to improve the quality of research, and therefore,
225 improve the quality of life of patients.

226 *“The goal was to include PPI members as research partners throughout the entire*
227 *research process. We wanted to do this in order to improve the quality, relevance,*
228 *and acceptability of the research for people with MS” – Researcher form.*

229 *“To improve the quality of the research, which would ultimately improve the quality*
230 *of life of people living with MS, in particular their cognition.” – PPI member form*

231 In terms of resources, both agreed that sufficient time was given to learn about the project
232 and for PPI members to provide input and deliberation in the process. Each form found that
233 training materials were provided, however, the PPI form added that while they were given a
234 manual, *“there was no training on how to perform my role”*(PPI member form).

235 The researcher and PPI member survey concluded that managing expenses was an issue for
236 PPI members. They were compensated for their contribution by gift card, salary or one-off
237 payment directly into their bank account. The researchers found difficulty with timely
238 distribution of compensation (though this may have been more so an artefact of institutional
239 finance procedures than a reflection on researcher motivations).

240 In total, six PPI members were involved and were recruited through engaging a voluntary
241 organisation relevant to the trial's focus (i.e. multiple sclerosis). While both teams found that
242 this working environment created trust and respect for individual realities and mutual
243 learning, the PPI team member was unsure if they initially felt prepared to work with the
244 research team. There was mutual agreement that sufficient time for gaining familiarity with
245 the trial and for input and deliberation was granted. The research team stated they identified
246 health needs and catered for them by allowing accessible facilities for in-person meetings;
247 however, the PPI member team found these facilities unsuitable for their needs.

248 *“When meeting took place in person, we ensured parking was available nearby and*
249 *accessible buildings were used. Meetings were held at a time that suited PPI*
250 *members.” – Researcher form*

251 *“The university found it very difficult to find a place for me to store a mobility*
252 *scooter, and the eventual location was not suitable. The disabled toilets were not*
253 *solely for disabled people, but for everyone, which defeats their purpose. The*
254 *university did not provide me with equipment supports, which I had to provide from*
255 *my own resources.” – PPI member form*

256 There were reciprocal views that the language used within intervention materials was
257 translated into ‘plain English’ from academic language. The PPI checklist expressed that
258 without experience or background in teamwork, PPI members may struggle to perform their
259 role.

260 *“I had experience in my previous work life of working in groups, and I also had*
261 *experienced what research is like when I was doing my degree. This made the role*
262 *easier for me, however, if I didn't have this prior knowledge, it would have been more*
263 *difficult to perform the role.” – PPI member form*

264 There was mutual agreement that the participants represented the target population; however,
 265 the research team did not make an extra effort to include underserved communities (e.g.
 266 given that underserved communities were not the target focus of the research, rather those
 267 with multiple sclerosis). Both surveys found that communication methods were adequate and
 268 allowed for honest conversations to support new ideas and decisions. The two forms also
 269 agreed that these methods were flexible as engagement was forced online due to the COVID-
 270 19 pandemic. PPI member involvement allowed contribution and implementation to decision-
 271 making. Table 5, below, summarises the main points from this theme from the perspective of
 272 the researcher and the PPI member.

273

274 **Table 5 - Summary of results from completed Researcher, and PPI Member EPPiIC in the**
 275 **Policy and Practice theme.**

Policy and Practice	
Researcher	PPI Member
Planned Strategy & Methods	
<ul style="list-style-type: none"> - The purpose of engagement was to shape study design, establish networks, dissemination of materials, providing support/ advice; and to enhance the quality and acceptability of the research for people with MS. - PPI strategy was planned so partnership involved recruitment documentation, study requirements and burden for participants discussion, content of acceptability interviews, dissemination of findings and experiences. - Embedded patient researcher was hired and predicted compensation breakdown was planned. This included budget for travel, subsistence, and time. 	<ul style="list-style-type: none"> - The reason for PPI and overall project was explained to PPI members. - PPI members were unsure of the PPI plans for the project at the beginning. - PPI members expected the researchers to show things connected with the trial, such as documents, manuals, to see if they were suitable for people living with multiple sclerosis. - Goals were to improve quality of research, to improve the quality of life of people living with MS.
Resource Mobilisation	
<ul style="list-style-type: none"> - Agreed that there was enough time provided for PPI members to learn about the project, and for input and deliberation. - There were clearly identified and adequate PPI resources and facilities within the institution for engagement. - PPI members received participation information sheet, participant manual, and COB-MS training videos as training materials. 	<ul style="list-style-type: none"> - Agreed that there was enough time provided for PPI members to learn about the project, and for input and deliberation. - Training was provided on an event basis. EPR was asked to prepare a Patient Information Sheet. EPR was provided with a manual about the project but no resources on how to perform their role.

<ul style="list-style-type: none"> - 5.8% of usable funding was spent solely on PPI efforts, with main areas including EPR salary, travel costs, PPI consultation fees, COVID-19 related meetings. - Managing expenses was an issue for PPI members, and there were challenges with distribution of compensation in a timely manner. - PPI members were categorised as staff and reimbursement was given in the form of Gift cards, salary, and bank transfers. 	<ul style="list-style-type: none"> - PPI members were introduced to the other team members face-to-face, and online during the COVID-19 pandemic. - Managing expenses was an issue for PPI members, in that the reimbursement was often insufficient to cover travel, sustenance and time spent. - Compensation was provided in the form of a salary for the role of EPR.
Reports of PPI	
<ul style="list-style-type: none"> - PPI members were involved in all areas of research, apart from as co-researchers in data analysis. - Involvement in every other stage was considered “very important”, except in ‘identification of Research Topic’. 	<ul style="list-style-type: none"> - EPR relationship with the trial lasted 36months. - They considered all areas of the trial that they were involved in important, except the “Identification of the research topic”. They were unsure of the significance of PPI member involvement in the steering groups (to note the EPR was not a member of this group).
Recruitment	
<ul style="list-style-type: none"> - Six PPI members were recruited in during the trial, by researchers approaching the patient organisation (MS Ireland). 	<ul style="list-style-type: none"> - EPR was recruited to the trial through an advertisement in the MS Society of Ireland Research Newsletter.
Team Engagement	
<ul style="list-style-type: none"> - Researchers felt themselves and the team were well prepared to work with PPI, and that no concerns were expressed by PPI members. - There was a commitment to understanding community cultures and past experiences of PPI members. - The ability to meet people in a setting familiar to them was considered, and language was translated into accessible language to facilitate understanding. - Health needs were identified as in-person meetings were held in accessible facilities with nearby parking, and at a time that suited PPI members. - During the COVID-19 pandemic, phone stands were given to participants to facilitate online engagement. 	<ul style="list-style-type: none"> - EPR was unsure if all PPI members felt prepared to work with researchers. - There was an environment for trust, respect and mutual learning, and the team acted to understand cultures and past experiences of members. - They did express concerns over their treatment by the team; however the issue was resolved by speaking with the PI of the team. - Academic language was translated into plain English, PPI members were not consulted for this translation, however, the research team explained any terms necessary. - The EPR expressed that they had previous experience of working in a team, however, felt that anyone without this knowledge might struggle to preform that role.
Adaptability	
<ul style="list-style-type: none"> - A feedback loop was used to communicate. - The PPI role changed from PPI member to embedded patient researcher. - Tasks were developed as the trial continued. - There was flexibility and an environment for experimental knowledge, trust, and respect. - PPI members viewed the experience as positive and fulfilling. 	<ul style="list-style-type: none"> - A feedback loop was used to communicate. - The PPI member role changed from how it was defined from the outset. - PPI members viewed the experience as positive and fulfilling.
Experience & Representation	
<ul style="list-style-type: none"> - The researcher team has no lived experience of the topic. 	<ul style="list-style-type: none"> - The PPI members felt that their group was representative of the target population, and slightly agreed that the needs of the PPI members were considered prior to the project.

<ul style="list-style-type: none"> - They had previous experience of working with PPI but viewed that experience somewhat negatively. - In contrast, they viewed this experience as highly positive. - There was a slight agreement that the six PPI member-group was a representative of the target population; however, it was disagreed that there had been an effort to include underserved communities. 	
Communication Methods	
<ul style="list-style-type: none"> - Communication strategies were used that allowed for open dialogue, honest exchange of ideas, and conversation regarding issues. - It was slightly agreed that flexible communication methods were used to accommodate all participants, using email, phone and in-person meetings. - COVID-19 pandemic forced a change engagement to online interaction. 	<ul style="list-style-type: none"> - The team communicated to PPI members in an appropriate manner that allowed for open dialogue, honest exchange of ideas and conversations regarding issues. - It was strongly agreed that flexible communication methods were used to accommodate all participants, through online engagement, however, without the aid of the institution.
Management, & Implementation of PPI Recommendations	
<ul style="list-style-type: none"> - PPI members contributed to relevant decisions in a meaningful and substantive way. 	<ul style="list-style-type: none"> - PPI members contributed to decisions in a meaningful and substantive way.

276

277 **Participatory Culture**

278 The second thematic section of the EPPIIC reported that PPI inclusion in this trial led to
 279 further collaborations between the research team and PPI members (e.g. in joint presentations
 280 and articles not directly related to the COB-MS). Reports were also provided on PPI
 281 members co-presenting results of the research and their perspectives to different audiences.
 282 One PPI member, to date, was cited as a co-author, while the PPI group have been
 283 acknowledged on multiple publications. Involvement in research facilitated the PPI members
 284 to gain knowledge on how PPI can influence the quality of research.

285 *“I am more knowledgeable of the research process and know how the patient can*
 286 *help improve the quality of research.”* – PPI member form

287 Further results are presented from this section in Table 6.

288

289

290

291 **Table 6 - Summary of results from Researcher and PPI Member EPPIIC under the theme of**
 292 **Participatory Culture**

Participatory Culture	
Researcher	PPI Member
Boosting Awareness	
<ul style="list-style-type: none"> - PPI members co-presented the results of research / their perspective by writing a blog posts, providing keynote speeches, presenting oral and poster presentations to lay and scientific audiences. - PPI members were not asked to use their personal contacts to send the results to a wider audience. - PPI led to collaboration with other national and international groups. - One PPI member (to date) named as a co-author on publications, while the PPI group are acknowledged on multiple publications. 	<ul style="list-style-type: none"> - The EPR co-presented the results of the research, or their perspective at many functions, in many different formats, and to many different audiences. - The trial also led to collaboration with national and international groups. - Personal and/or professional skills changed in that the EPR found they became more knowledgeable of the research process and how patients can improve the quality of research. - The EPR was cited as an author / contributor on many COB-MS research outputs.
Participatory Feedback	
<ul style="list-style-type: none"> - The EPR had the opportunity to provide feedback on their participation through this checklist. However, feedback was not sought from the wider PPI groups as it was not included in the ethics application. 	<ul style="list-style-type: none"> - Sufficient PPI feedback was provided to PPI members throughout the trial. - PPI members were asked to provide feedback throughout. This was done at weekly meetings.

293

294 **Influencing the Outcomes of PPI**

295 The final section of the EPPIIC focused on the strengths of and challenges faced by PPI in
 296 the COB-MS trial. Specific examples included challenges in organisation of meetings when
 297 PPI were not responsible for chairing them, as well as wider organisational constraints such
 298 as the institution’s processes around payment. The PPI member reported challenges with the
 299 facilities of the institution but found that a clear sense of purpose was gained from their
 300 involvement in the study.

301 *“I was able to use my experience of something negative, chronic illness, for*
 302 *something positive. It gave me a purpose again.”* – PPI member form

303 Conceptual developments that emerged concerned the creation of the role of ‘*Embedded*
 304 *Patient Researcher*’. This role was defined as it involved a greater depth of involvement in
 305 comparison to the PPI advisory panel. This was the first time this had been done in this

306 institution. The research team also identified ‘thorough evaluation’ as an important
 307 consideration for future PPI inclusion.

308

309 **Table 7 - Summary of notes and ideas in Researcher and PPI Member EPPIIC under the**
 310 **theme of Influencing the Outcomes of PPI**

Influencing the Outcomes of PPI	
Researcher	PPI Member
<ul style="list-style-type: none"> - Challenges of PPI in this trial included inclusion of PPI members when meetings were not chaired by the research team, and retention of PPI members during the COVID-19 pandemic due to unfamiliarity with Zoom/online meetings. - The university’s process surrounding payment hindered the reputation of PPI in the trial. - Motivation from the PPI panel and EPR enabled the impact of PPI. - Having an EPR made the wider PPI tasks more successful and easier to manage. - The term ‘<i>Embedded Patient Researcher</i>’ was coined. - The researcher would be likely to involve PPI in future research. - Positive impacts on PPI in research included recruitment, developing patient materials, integration, engagement with trial participants, communication & dissemination plan, and collaboration. 	<ul style="list-style-type: none"> - Challenges of PPI inclusion: 1) the university facilities were often not appropriate for the PPI members; and 2) did not provide any equipment resources. - PPI member quality of life changed as their involvement allowed them to create a positive outcome from a negative situation and helped them find purpose. - In the future, a buddy system could be proposed to involve inexperienced PPI members. - Currently the social welfare system in Ireland does not permit people in receipt of some payments to engage in PPI research. - The EPR would be likely to participate in PPI research again. - Positive impacts of PPI on the research were the patient information sheet, participant manual, phone stand, newsletter, etc. - No negative experiences of PPI on research were identified.

311

312

313 **Discussion**

314 The variety of Public and Patient Involvement typologies brings forth great challenge in the
 315 development of suitable evaluation tools, applicable across wide-ranging PPI scenarios.

316 Many agree that no individual assessment method can be used (21), which is a barrier to
 317 comparing PPI between trials (27). However, it may be the case that there is a lack of

318 checklists providing sufficient flexibility to assess different PPI contexts. As developed in the
 319 current research, the EPPIIC may have the necessary adaptability, as it provides space and

320 opportunities for expression of PPI efforts, in broader contexts, that more specific questioning

321 may miss. While the primary goal of such evaluation exists as an effort to improve PPI
322 standards for future research, identifying tokenistic trials that include PPI just as part of an
323 ‘integrated research agenda’ is also crucial (37). Although challenging, through consideration
324 of comprehensiveness and attention to PPI specific questioning, it is possible to compare and
325 contrast the strengths and weaknesses of various trials.

326 **Overall Interpretation of Results**

327 Results from our research suggest that the use of open-ended responding at the end of each
328 theme facilitated flexibility in reporting on topics not otherwise addressed.

329 Notably, a joint qualitative and quantitative approach responding/assessing is seldom used in
330 other checklists but is a necessary component to include for purposes of ensuring a
331 comprehensive evaluation. Qualitative research allows open questioning to assess opinions
332 which allows broader understanding when compared to asking direct quantitative questions
333 (39). Using open ended questions also allowed for individualised insight within concepts, a
334 much-valued aid in further improvement and assessment, which helps to avoid the ‘tyranny
335 of majority’, in which the generalised opinion dominates individual voices (40), particularly
336 in specific contexts, like those that arise in research interventions This is important in
337 encouraging diverse groups to participate in trials, as facilitating PPI means accommodating
338 to each member’s reality, instead of allowing a needs assessment hospitable to the majority to
339 cover all participants (25).

340 The EPPIIC, developed in the current research, includes process and outcome metrics,
341 differing from some tools that only consider process-based evaluation (30). The themes
342 included in the checklist identify the seemingly most vital areas of PPI in research (e.g.
343 practice, culture, and outcomes). Importantly, this checklist can also be used when planning
344 PPI activities – see Figure 1 below:

345 **Fig 1. Considerations for Establishing PPI, adapted from the EPPIIC**

346 The largest section of the EPPIIC centres around the structural organisation of PPI within
347 studies, a considerable area of downfall in previous PPI trials (32). These questions used
348 within the framework pose as surrogates for understanding the factors that led to ‘good’ or
349 ‘bad’ involvement experiences; for example, with respect to training or reimbursement (33).
350 Some questioning requires an understanding of perspective; for example, participants
351 agreeing that they would participate in the future reflects a positive outlook on their
352 experience (28).

353 The themes were developed to thoroughly understand the levels of integration of PPI within
354 trials. Often trials adapt the ‘one-off model’ meaning the research team has decided to
355 include PPI for a specific reason, without considering the wider benefits of collaboration
356 (35). It is often more transactional, with PPI members filling a consultant role rather than as a
357 fellow researcher. Alternatively, the ‘fully intertwined model’ focuses on true participation
358 and PPI member integration within the trial. It reflects the true purpose of PPI and adds the
359 potential to gain all possible benefit, for both the research and the PPI team. Awareness of the
360 approach of integration used reveals the level of consideration and preparation made to
361 include PPI.

362 The use of two separated perspectives (researcher and PPI member) provided opportunity for
363 divergent focuses which is a vital component of PPI, (28;40). Highlighting disparity in
364 opinions between participants is the first step in improving future efforts and reinforces the
365 efficacy of PPI methods. In order to provide their opinions, evaluators must be in an
366 environment of honesty, openness, and respect (31). Providing separate EPPIICs to both
367 researchers and PPI members facilitated this, as one form was not influenced by the opinions
368 of others. In consideration of the PPI member’s checklist, it was important to adapt the

369 checklist's language to ensure accessibility and avoid unnecessarily technical jargon and
370 terminology. Other than amendments to language and phrasing, the questions in each
371 checklist remained largely a reflection of each other.

372 The application of the EPPIIC to the COB-MS feasibility trial provided insight into PPI
373 factors that were beneficial and those that were challenging. The 'Policy and Practice' theme
374 revealed that there was general agreement over the reasoning for including PPI in the
375 research and the development of an environment of respect and trust. There was slight
376 disparity within the suitability of facilities used and training resources mobilised. A good
377 relationship between PPI members and researchers was revealed, with any conflict being
378 found to be constructive and yielding an acceptable solution. There was a pre-planned
379 structure to the inclusion and engagement of PPI within COB-MS, which other similar
380 studies/partnerships have lacked, thus leading to subsequent deterioration of collaboration
381 (41). A review assessing the impact of PPI within MS specific trials found that while many
382 different approaches may be taken, inclusion in 'trial design' was crucial to giving PPI
383 members power to impact the research and various communication channels are required to
384 enhance participation, as utilised in this trial (42). Other consistent findings between the
385 current research and Gray and colleagues' review (42) were included the attitude of PPI
386 members towards research, as well as the importance and methods of reimbursement. The
387 benefits of PPI organisation and practice were reflected in the decisions that led to higher-
388 quality research, as a direct result of PPI.

389 The theme of 'Participatory culture' showed a 'fully intertwined' partnership as PPI members
390 were involved in citation and publication. The impact of PPI in this trial also led to further
391 collaborations for the PPI members and researchers. The team sought feedback from the PPI
392 team to allow them to express any concerns. This shows a true effort to involve the PPI team

393 as fellow researchers and reflected a good relationship between the researcher and PPI
394 member team.

395 The assessment of outcome-based metrics was included within the ‘Influencing the outcomes
396 of PPI’ section. This again reflected that while accommodations were made for PPI
397 involvement, the institution did not seem entirely suitable for PPI members to access. For
398 example, a lack of equipment supports or facilities to store mobility aids. However, this was
399 overcome, to some extent, by the adaptation of online meetings during the COVID-19
400 pandemic. This theme also exhibited insight into the effect of involvement for PPI members,
401 as they found purpose in increasing the quality of research – feeling the ability to turn their
402 negative experiences into positive input into possible clinical intervention. Positive impacts
403 that PPI brought further included recruitment, proper engagement with participants,
404 developing patient materials and communication and collaboration. Both parties agreed that
405 they would get involved in PPI research in the future, reflecting a positive outlook on their
406 own involvement.

407 **Limitations and Considerations for Future Research**

408 Another step towards achieving an ideal PPI evaluation in future research would be the use of
409 a possible weighted scoring system for the EPPIIC, where “positive” and “negative” PPI
410 factors could be evaluated within each theme and metricised. An example of the ‘Rifkin
411 Spider-gram’ (25) being applied to PPI evaluation using the EPPIIC is shown below in Figure
412 2.

413 **Fig 2: Spidergram displaying example of scoring system for PPI evaluation, using**
414 **overarching themes as described previously.** This example shows a score of 9 for Policy &
415 Practice, 6 for Participatory Culture, and 4 for Influencing Outcomes of PPI.

416 However, as not all questions might receive the same weighting, as one factor could be
417 deemed more crucial to PPI than another, a weighted system would have to be decided within
418 a cohort of PPI members and researchers, which was not possible to carry out in this study.
419 Another challenge of implementing a scoring system is the decision of what would constitute
420 ‘positive’ and ‘negative’ PPI impacts (13), as this is likely to vary considerably across
421 trials/research settings. An example of such a scoring/weighting system is used by the STEPP
422 guideline, in which PPI inspired changes to the study are valued as a positive impact.
423 However, in reality, non-implementation of such changes is not always a bad thing. The PPI
424 that is shown in this instance is the ability of the research and PPI team to collaborate and
425 discuss the issue and why a proposed solution is not possible, or maladaptive to the research.
426 Therefore, the labelling of right and wrong needs to be carefully considered. It might also be
427 suggested that such a weighting system might be arbitrary in the light of the potential
428 richness that can be achieved through qualitative responding, as is the case for the current
429 checklist.

430 Another area for future research would be the an evaluation of PPI throughout the trial, rather
431 than just at the end (31). This feedback could guide PPI efforts to engage more efficient
432 methods within the trial and make amendments, as necessary, in real time. Short assessments
433 following meetings evaluating the effectiveness of communication and involvement aid the
434 effort to improve future meetings and collaboration. Such an evaluation could also give all
435 team members an opportunity to express any issues or queries anonymously, so that their
436 concerns may be discussed at subsequent meetings. The EPPIIC was applied retrospectively
437 to the COB-MS feasibility trial, however, in the future, an evaluation could be carried out
438 alongside the research itself (e.g. once every three or six months, perhaps relative to the
439 research’s life-cycle), presenting an opportunity to compare the final assessment to
440 understand the impact of continuous evaluation.

441 **Conclusion**

442 The EPPIIC, as developed in the current research, expressed a constructivist paradigm that
443 focuses on reflection and notation for future improvement rather than a cynical criticism of
444 possible shortcomings. Having both PPI and Researcher forms of the EPPIIC available
445 allowed for flexibility to evaluate any interventional study using PPI methods. It is hoped
446 this tool leads to further improvement within PPI methods to facilitate use in increasing
447 numbers of clinical trials and studies that will pave the way for optimal research and clinical
448 developments in the years to come.

449 Overall, the inclusion of PPI within this trial was highly beneficial and was carried out well
450 within the COB-MS team. There is evidence of the maintenance of a good relationship
451 between parties, which is crucial to enabling proper (and future) involvement (26). The
452 separate EPPIICs allowed for people to express their thoughts and opinions regarding
453 components of PPI. By comparing perspectives, both strengths and weaknesses of PPI in this
454 trial were highlighted. Adaptation and flexibility were exhibited throughout the trial, which
455 appeared to lead to the achievement of high-quality PPI. Both parties independently
456 expressed recommendations for future improvements, which is the ideal objective of PPI
457 evaluation (37). The EPPIIC worked well to highlight the organisation of PPI and the culture
458 created within the team.

459 The findings from this research suggests potential for the EPPIIC's use in future research, as
460 appropriate. We invite researchers and PPI members alike to use the checklist as a means of
461 evaluating PPI within their own research.

462

463 **Acknowledgements**

464 We wish to acknowledge the invaluable support and input from the COB-MS PPI group
465 throughout this research and the associated COB-MS work.

466 **Supporting Information**

467 **S1 Appendix. Evaluation of PPI for Interventional research Checklist (EPPiIC).** EPPiIC
468 (PPI Version)

469 **S2 Appendix. Evaluation of PPI for Interventional research Checklist (EPPiIC).** EPPiIC
470 (Researcher Version)

471 **References**

- 472 1. Hewlett S, Wit M, Richards P, Quest E, Hughes R, Heiberg T, et al. Patients and
473 professionals as research partners: challenges, practicalities, and benefits. *Arthritis Rheum.*
474 2006;55(4):676-80.
- 475 2. Pizzo E, Doyle C, Matthews R, Barlow J. Patient and public involvement: how much
476 do we spend and what are the benefits? *Health Expect.* 2015;18(6):1918-26.
- 477 3. Jackson D, Moorley C. 'Nothing about us without us': embedding participation in peer
478 review processes. *J Adv Nurs.* 2022;78(5):e75-e6.
- 479 4. Selman LE, Clement C, Douglas M, Douglas K, Taylor J, Metcalfe C, et al. Patient
480 and public involvement in randomised clinical trials: a mixed-methods study of a clinical
481 trials unit to identify good practice, barriers and facilitators. *Trials.* 2021;22(1):735.
- 482 5. Blackburn S, McLachlan S, Jowett S, Kinghorn P, Gill P, Higginbottom A, et al. The
483 extent, quality and impact of patient and public involvement in primary care research: a
484 mixed methods study. *Res Involv Engagem.* 2018;4:16.
- 485 6. Hoddinott P, Pollock A, O'Cathain A, Boyer I, Taylor J, MacDonald C, et al. How to
486 incorporate patient and public perspectives into the design and conduct of research.
487 *F1000Res.* 2018;7:752.
- 488 7. Joyce R, Dwyer CP & Hynes S. M. (2021). Twelve months into a feasibility trial:
489 reflections on three experiences of public and patient involvement in research [version 2; peer
490 review: 3 approved]. *HRB Open Research*, 4:11 <https://doi.org/10.12688/hrbopenres.13205.2>
- 491 8. Tomlinson J, Medlinskiene K, Cheong VL, Khan S, Fylan B. Patient and public
492 involvement in designing and conducting doctoral research: the whys and the hows. *Research*
493 *involvement and engagement.* 2019 Dec;5:1-2.

- 494 9. Smits, D. W., Van Meeteren, K., Klem, M., Alsem, M., & Ketelaar, M. (2020).
495 Designing a tool to support patient and public involvement in research projects: the
496 Involvement Matrix. *Research involvement and engagement*, 6(1), 1-7.
- 497 10. Russell J, Fudge N, Greenhalgh T. The impact of public involvement in health
498 research: what are we measuring? Why are we measuring it? Should we stop measuring it?.
499 *Research involvement and engagement*. 2020 Dec;6:1-8.
- 500 11. Boivin A, L'Esperance A, Gauvin FP, Dumez V, Macaulay AC, Lehoux P, et al.
501 Patient and public engagement in research and health system decision making: A systematic
502 review of evaluation tools. *Health Expect*. 2018;21(6):1075-84.
- 503 12. Greenhalgh T, Hinton L, Finlay T, Macfarlane A, Fahy N, Clyde B, et al. Frameworks
504 for supporting patient and public involvement in research: Systematic review and co-design
505 pilot. *Health Expect*. 2019;22(4):785-801.
- 506 13. Rowe G, Frewer, L. J. . *Public Participation Methods: A Framework for Evaluation*.
507 *Science, Technology, & Human Values*. 2000;25(1):3-29.
- 508 14. Dwyer, C.P., Alvarez-Iglesias, A., Joyce, R., Counihan, T. J., Casey, D. & Hynes,
509 S.M. (2020). Evaluating the feasibility and preliminary efficacy of a Cognitive Occupation-
510 Based programme for people with Multiple Sclerosis (COB-MS): protocol for a feasibility
511 cluster-randomised controlled trial. *Trials*, 21(1), 269. [https://doi.org/10.1186/s13063-020-](https://doi.org/10.1186/s13063-020-4179-5)
512 [4179-5](https://doi.org/10.1186/s13063-020-4179-5)
- 513 15. Dwyer, C.P., Alvarez-Iglesias, A., Joyce, R. Counihan, T. J., Casey, D. & Hynes,
514 S.M. (2023). Evaluating the feasibility and preliminary efficacy of a Cognitive Occupation-
515 Based programme for people with Multiple Sclerosis (COB-MS): an update to the protocol
516 for a feasibility cluster-randomised controlled trial. *Trials* 24, 48.
517 <https://doi.org/10.1186/s13063-023-07080-y>

- 518 16. Cooke, A., Smith, D., & Booth, A. (2012). Beyond PICO: the SPIDER tool for
519 qualitative evidence synthesis. *Qualitative health research*, 22(10), 1435-1443.
- 520 17. Braun V, Clarke V. One size fits all? What counts as quality practice in (reflexive)
521 thematic analysis?. *Qualitative research in psychology*. 2021 Jul 3;18(3):328-52.
- 522 18. Byrne D. A worked example of Braun and Clarke's approach to reflexive thematic
523 analysis. *Quality & quantity*. 2022 Jun;56(3):1391-412.
- 524 19. Garratt A, Sagen J, Borosund E, Varsi C, Kjekken I, Dagfinrud H, et al. The Public and
525 Patient Engagement Evaluation Tool: forward-backwards translation and cultural adaption to
526 Norwegian. *BMC Musculoskelet Disord*. 2022;23(1):556.
- 527 20. Public and Patient Engagement Collaborative MU. Public and Patient Engagement
528 Evaluation Tool (PPEET). 2018.
- 529 21. Group PS. The Public Involvement Impact Assessment Framework: Executive
530 Summary. Lancaster University; 2014.
- 531 22. System HPOIH. Engagement Toolkit. 2016.
- 532 23. Maybee A, Clark, B., McKinnon, A., Angl, E. N. Patients as Partners in Research:
533 Patient/Caregiver Surveys Patients Canada; 2016.
- 534 24. Maybee A, Clark, B., McKinnon, A., Angl, E. N. Patients as Partners in Research:
535 Researcher Surveys Patients Canada; 2016.
- 536 25. Rifkin SB, Muller F, Bichmann W. Primary health care: on measuring participation.
537 *Soc Sci Med*. 1988;26(9):931-40.
- 538 26. Committee NCE. Framework for Public Involvement in Clinical Effectiveness
539 Processes. 2018.
- 540 27. South J, Fairfax P, Green E. Developing an assessment tool for evaluating community
541 involvement. *Health Expect*. 2005;8(1):64-73.

- 542 28. Dukhanin V, Topazian R, DeCamp M. Metrics and Evaluation Tools for Patient
543 Engagement in Healthcare Organization- and System-Level Decision-Making: A Systematic
544 Review. *Int J Health Policy Manag*. 2018;7(10):889-903.
- 545 29. Foley L, Kiely B, Croke A, Larkin J, Smith SM, Clyne B, et al. A protocol for the
546 evaluation of the process and impact of embedding formal and experiential Public and Patient
547 Involvement training in a structured PhD programme. *J Multimorb Comorb*.
548 2021;11:26335565211024793.
- 549 30. Wilton P, Neville D, Audas R, Brown H, Chafe R. An Evaluation of In-Person and
550 Online Engagement in Central Newfoundland. *Healthc Policy*. 2015;11(2):72-85.
- 551 31. Arora PG, Krumholz LS, Guerra T, Leff SS. Measuring Community-Based
552 Participatory Research Partnerships: The Initial Development of an Assessment Instrument.
553 *Prog Community Health Partnersh*. 2015;9(4):549-60.
- 554 32. Woodland RH, Hutton, M. S. Evaluating Organisational Collaborations: Suggested
555 Entry Points and Strategies. *American Journal of Evaluation*. 2012;33(3):366-83.
- 556 33. Staniszewska S, Brett J, Simera I, Seers K, Mockford C, Goodlad S, et al. GRIPP2
557 reporting checklists: tools to improve reporting of patient and public involvement in research.
558 *Res Involv Engagem*. 2017;3:13.
- 559 34. Council SH. The Participation Toolkit: Supporting Patient Focus and Public
560 Involvement in NHS Scotland 2014.
- 561 35. Wilson P, Mathie E, Keenan J, McNeilly E, Goodman C, Howe A, et al. ReseArch
562 with Patient and Public invOLvement: a RealisT evaluation - the RAPPORT study. *Health
563 Services and Delivery Research*. Southampton (UK)2015.
- 564 36. Broerse JE, Zweekhorst MB, van Rensen AJ, de Haan MJ. Involving burn survivors
565 in agenda setting on burn research: an added value? *Burns*. 2010;36(2):217-31.

- 566 37. Abma TA, Broerse JE. Patient participation as dialogue: setting research agendas.
567 Health Expect. 2010;13(2):160-73.
- 568 38. Kreindler SA, Struthers A. Assessing the organizational impact of patient
569 involvement: a first STEPP. Int J Health Care Qual Assur. 2016;29(4):441-53.
- 570 39. Cleland JA. The qualitative orientation in medical education research. Korean J Med
571 Educ. 2017;29(2):61-71.
- 572 40. Tritter JQ, McCallum A. The snakes and ladders of user involvement: Moving beyond
573 Arnstein. Health Policy. 2006;76(2):156-68.
- 574 41. Hughes J, Weiss J. Simple rules for making alliances work. Harv Bus Rev.
575 2007;85(11):122-6, 8, 30-1 passim.
- 576 42. Gray E, Amjad A, Robertson J, Beveridge J, Scott S, Peryer G, et al. Enhancing
577 involvement of people with multiple sclerosis in clinical trial design. Mult Scler.
578 2023;29(9):1162-73.
- 579

Figure 1





Figure 1: Considerations for Establishing PPI, adapted from the EPPIIC

Figure 2



medRxiv preprint doi: <https://doi.org/10.1101/2024.03.17.24304433>; this version posted March 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure2: Spidergram displaying example of scoring system for PPI evaluation, using overarching themes as described previously. This example shows a score of 9 for Policy & Practice, 6 for Participatory Culture, and 4 for Influencing Outcomes of PPI.